FY2024 · ended Dec 31, 2024 · Revenue $0 · Filed Mar 11, 2026
Minerva Neurosciences, Inc. (NERV) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
$0
Net income
$-293.42M
-20492.7% vs prior year
Operating cash flow (TTM)
$-26.17M
-67.4% vs year-ago TTM
Free cash flow
$-24.66M
-911.1% vs prior year
EPS
$-34.67
-18347.4% vs prior year
Dividend per share
None
Shares outstanding
43.27M
+518.8% vs prior year
Net cash
$25.25M
FY 2020
Operating margin
4.5%
FY 2020
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NERV (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- MA
- Headquarters
- Burlington, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1598646
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $0 | $0 |
| Operating income | -$15.1M | -$21.8M | -$23.1M | -$25.2M | -$45.4M |
| Net income | -$293.4M | $1.4M | -$30.0M | -$32.1M | -$49.9M |
| Diluted EPS | -$34.67 | $0.19 | -$4.61 | -$6.01 | -$9.35 |
| Operating cash flow | -$13.5M | -$19.6M | -$14.8M | -$24.6M | -$24.6M |
| Free cash flow | — | — | — | -$24.7M | — |
| Total assets | $98.0M | $37.1M | $56.9M | $55.1M | $77.1M |
| Total liabilities | $233.8M | $62.8M | $85.4M | $75.1M | $69.1M |
| Stockholders' equity | -$140.7M | -$25.7M | -$28.5M | -$20.0M | $8.0M |
| Cash and investments | $82.3M | $21.4M | $40.9M | $36.1M | $60.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Aug 12, 2026 | Aug 10, 2026 |
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2026 | Aug 7, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Shareholder vote results
|
Jun 4, 2026 | Jun 3, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
May 27, 2026 | May 27, 2026 |
| 10-Q | Quarterly report | May 5, 2026 | Mar 31, 2026 |
All 645 Minerva Neurosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.